Press Releases

GB Sciences Files Provisional Patent Application for the Treatment of COVID-19-Related Acute Respiratory Distress Syndrome (ARDS), the Leading Cause of Hospitalization and Deaths, Utilizing Its Cannabinoid Containing Complex Mixtures (CCCM(TM))

GB Sciences Announces Issuance of US Patent for Its Proprietary Pain Formulations for the 560 Billion Dollar Chronic Pain Treatment Market

GB Sciences Announces Issuance of US Patent for Its Proprietary Cannabinoid-Based Formulations for Parkinson’s Disease

GB Sciences Completes and Achieves Statistical Significance in Preclinical Study of Its Proprietary Parkinson’s Disease Cannabinoid Formulations and Begins Mechanism of Action Study With the National Research Council of Canada

GB Sciences Announces the Sale of The Majority Interest in Nevada Cultivation Operations to Focus on Its First Two Cannabinoid-Based Medical Compounds for Parkinson’s Disease and Neuropathic Pain

GB Sciences Welcomes Esteemed Patent and Intellectual Property Attorney, Mr. Edmond DeFrank, to Its Board of Directors

GB Sciences in Benzinga Piece

GB Sciences Launches Global Expansion in Canada with GBS Global Biopharma, Inc.

GB Sciences Supports the Position of LSU AgCenter: Allegations Made by Commissioner Are Untrue

Statement From LSU AgCenter on False Allegations Made by LDAF Commissioner

GB Sciences Co-Authors a Peer-Reviewed Article Showing that Heart Failure Can Be Mitigated

GB Sciences Team to Present at Digital Hollywood Forum

DEA Rescheduling Benefits GB Sciences

Catalent to Provide Parkinson’s Therapy Delivery Systems

GB Sciences and University of Athens, Greece, Embark on Next-Level Drug Discovery

Nine Pharmacies to Serve Louisiana

First Quarter Revenue

Peer-Reviewed Article for American Heart Association

GB Sciences Strengthens Compliance Program

VERMONT’S GARDENING EXPERIMENT

Researchers Name GB Sciences in Top 10

GB Sciences Files New Provisional Patent

GB Sciences Files New Patents

Radio Interview: John Poss on Bill Martinez Live

Watch this short video of GBLX CEO John Poss as he fields questions from the web

Video: CEO John Poss talks European Trials

Watch this short video of GBLX CEO John Poss as he fields questions from the web

Video: CEO John Poss talks Rec vs. Science

Watch this short video of GBLX CEO John Poss as he fields questions from the web

Video: CEO John Poss talks CBD, Cura, Hemp

Watch this short video of GBLX CEO John Poss as he fields questions from the web

Cannabis: the Early Years and What They Teach Us

MISSOURI

MIS

COLORADO

CNN: Patients turn to pot over pills

Video: What is a Cannabinoid?

The State of Alaska: Boom or Bust?

GB Seeks Minor Cannabinoids for Patient Studies

Louisiana House backs expansion of medical cannabis program

Video: CEO John Poss on a “Small but Complex” Company

Watch this short video of GBLX CEO John Poss as he fields questions from the web

Video: CEO John Poss on Jeff Sessions

Watch this short video of GBLX CEO John Poss as he fields questions from the web

New VP and General Counsel

GB Sciences and Parkinson’s Disease

YouTube: Spinach Veins Replace Human Blood Vessels

CEO John Poss Interview

GB Sciences Partners with Wellcana Group in Louisiana

News from Washington D.C.

Scientific Advisory Board Expands

Dr. Small-Howard invited to Neuroscience Forum

GB Sciences: Research is in our Corporate DNA

Tissue Culture Propagation Breakthrough

GB Sciences is “Happy”

GBScience Forms Science Advisory Board

How did they balance being so funny and being such respected artists?” This question was recently posed by a visitor in reference

400% Sales Increase

How did they balance being so funny and being such respected artists?” This question was recently posed by a visitor in reference

Research Collaboration in Spain

How did they balance being so funny and being such respected artists?” This question was recently posed by a visitor in reference